CGON FY 2025 G&A expenses rise 118.1% to USD 73.5 million

Reuters02-27
CGON FY 2025 G&A expenses rise 118.1% to USD 73.5 million

CG Oncology (CGON) reported a FY 2025 net loss attributable to common stockholders of USD 161.0 million and a Q4 2025 net loss attributable to common stockholders of USD 41.3 million. FY 2025 total revenues were USD 4.0 million, including USD 3.2 million in commercial and development revenue and USD 0.8 million in license and collaboration revenue. FY 2025 R&D expenses were USD 116.6 million and G&A expenses were USD 73.5 million, while Q4 2025 R&D expenses were USD 30.0 million and G&A expenses were USD 18.0 million. Cash, cash equivalents and marketable securities were USD 742.2 million as of Dec. 31, 2025, and CG Oncology said the balance was approximately USD 903.0 million as of Feb. 26, 2026 after raising net proceeds of about USD 98.4 million in Q4 2025 and about USD 188.0 million in January 2026 through its at-the-market facility; the company said it expects its cash to fund operations into H1 2029. On the pipeline, CG Oncology said Phase 3 topline data from PIVOT-006 evaluating cretostimogene as an adjuvant therapy in intermediate-risk NMIBC is expected in H1 2026, and first results from CORE-008 Cohort CX testing cretostimogene plus gemcitabine in high-risk NMIBC are expected in H1 2026. The company also reiterated plans to complete a BLA submission in 2026 for cretostimogene in high-risk BCG-unresponsive NMIBC with CIS with or without Ta/T1 disease, and highlighted SUO 2025 data including 3-, 6- and 9-month HG-EFS of 95.7%, 84.6% and 80.4% in BOND-003 Cohort P and an 88% CR in CORE-008 Cohort A.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602270830PRIMZONEFULLFEED9662527) on February 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment